<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665234</url>
  </required_header>
  <id_info>
    <org_study_id>MIM-726</org_study_id>
    <nct_id>NCT02665234</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease</brief_title>
  <official_title>A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mimetogen Pharmaceuticals USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mimetogen Pharmaceuticals USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic
      Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry
      eye disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Corneal Fluorescein Staining Using The Ora Calibra Scale</measure>
    <time_frame>Day 57</time_frame>
    <description>An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Discomfort Using The Ora Calibra Scale</measure>
    <time_frame>Day 57</time_frame>
    <description>A patient-reported subjective assessment of ocular discomfort recorded at each of the 5 office visits throughout the treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Corneal Fluorescein Staining Using The Ora Calibra Scale</measure>
    <time_frame>Day 15</time_frame>
    <description>An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Disease Index</measure>
    <time_frame>Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Dryness Using The Ora Calibra Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>A patient-reported subjective assessment of ocular dryness recorded twice daily over the complete treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>Tavilermide Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1% Tavilermide Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Ophthalmic Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Tavilermide Ophthalmic Solution</intervention_name>
    <description>1% Tavilermide BID Dosing</description>
    <arm_group_label>Tavilermide Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ophthalmic Solution</intervention_name>
    <description>Vehicle Ophthalmic Solution</description>
    <arm_group_label>Vehicle Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age.

          -  Provided written informed consent.

          -  Have a reported history of dry eye Have a history of use or desire to use eye drops
             for dry eye

        Exclusion Criteria:

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) at Visit
             1.

          -  Be diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or
             conjunctiva, within the last 12 months.

          -  Have any planned ocular and/or lid surgeries over the study period.

          -  Have corrected visual acuity greater than or equal to +0.7 as assessed by Early
             Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit .

          -  Have an uncontrolled systemic disease.

          -  Be a woman who is pregnant, nursing or planning a pregnancy.

          -  Be a woman of childbearing potential who is not using an acceptable means of birth
             control

          -  Have a known allergy and/or sensitivity to the test article or its components.

          -  Have a condition or be in a situation which the investigator feels may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with the subject's participation in the study

          -  Be currently enrolled in an investigational drug or device study or have used an
             investigational drug or device within 45 days of Visit 1 Be unable or unwilling to
             follow instructions, including participation in all study assessments and visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garth Cumberlidge, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mimetogen Pharmaceuticals USA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MIM-726 Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

